Identification of a potential biomarker panel for the intake of the common dietary trans fat elaidic acid (trans{increment}9-C18:1)

Journal of Proteomics

Volumn 75, Issue 9, 2012, Pages 2685-2696

  Krogager, Toke Peter ^a,b   Nielsen, Lone Vendel ^a,b   Bak, Steffen ^c   Young, Clifford ^c   Ferreri, Carla ^d   Jensen, Ole Nørregaard ^c   Højrup, Peter ^c   Thoma, Vladimiros ^d,e   Thøgersen, Ida B ^a   Enghild, Jan J ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d CNR   (Italy)

^e UNIVERSITY OF ATHENS   (Greece)

Author keywords

Elaidic acid; HepG2 cells; Plasma biomarker; Serum free; Trans fatty acids

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER; ELAIDIC ACID; MESSENGER RNA; OLEIC ACID; STEARIC ACID;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CULTURE MEDIUM; DNA MICROARRAY; FAT INTAKE; GEL ELECTROPHORESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BIOLOGICAL MARKERS; CARBON RADIOISOTOPES; CULTURE MEDIA; DIETARY FATS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEP G2 CELLS; HUMANS; LIVER; OLEIC ACID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEINS; RNA, MESSENGER; STEARIC ACIDS; TANDEM MASS SPECTROMETRY; TRANS FATTY ACIDS;

EID: 84860447783     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.03.023     Document Type: Article

References (65)

1. Mozaffarian D., Clarke R. Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr 2009, 63(Suppl. 2):S22-S33.
2. Hunter J.E. Dietary trans fatty acids: review of recent human studies and food industry responses. Lipids 2006, 41:967-992.
3. Mensink R.P., Zock P.L., Kester A.D., Katan M.B. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003, 77:1146-1155.
4. Mensink R.P., Katan M.B. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med 1990, 323:439-445.
5. Aro A., Jauhiainen M., Partanen R., Salminen I., Mutanen M. Stearic acid, trans fatty acids, and dairy fat: effects on serum and lipoprotein lipids, apolipoproteins, lipoprotein(a), and lipid transfer proteins in healthy subjects. Am J Clin Nutr 1997, 65:1419-1426.
6. Mozaffarian D., Katan M.B., Ascherio A., Stampfer M.J., Willett W.C. Trans fatty acids and cardiovascular disease. N Engl J Med 2006, 354:1601-1613.
7. Ascherio A., Katan M.B., Zock P.L., Stampfer M.J., Willett W.C. Trans fatty acids and coronary heart disease. N Engl J Med 1999, 340:1994-1998.
8. Lopez-Garcia E., Schulze M.B., Meigs J.B., Manson J.E., Rifai N., Stampfer M.J., et al. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr 2005, 135:562-566.
9. Stender S., Dyerberg J. The influence of trans fatty acids on health 2004, Fourth edition.
10. Stender S., Dyerberg J., Bysted A., Leth T., Astrup A. A trans world journey. Atheroscler Suppl 2006, 7:47-52.
11. Geeta Bansal W.Z., Tan Ting-Wei, Neo Fung-Leng, Lo Hui-Ling Analysis of trans fatty acids in deep frying oils by three different approaches. Food Chem 2009, 116:7.
12. Craig B.M., Murty N.L. Quantitative fatty acid analysis of vegetable oils by gas-liquid chromatography. J Am Oil Chem Soc 1959, 36:549-552.
13. Sebedio J.L., Christie W.W. Trans fatty acids in human nutrition 1998, Oily Press, Dundee.
14. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
15. Chun A.A., McGee S.R. Bedside diagnosis of coronary artery disease: a systematic review. Am J Med 2004, 117:334-343.
16. Pope J.H., Aufderheide T.P., Ruthazer R., Woolard R.H., Feldman J.A., Beshansky J.R., et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000, 342:1163-1170.
17. Panju A.A., Hemmelgarn B.R., Guyatt G.H., Simel D.L. The rational clinical examination. Is this patient having a myocardial infarction?. JAMA 1998, 280:1256-1263.
18. Swap C.J., Nagurney J.T. Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. JAMA 2005, 294:2623-2629.
19. Lopes S.M., Trimbo S.L., Mascioli E.A., Blackburn G.L. Human plasma fatty acid variations and how they are related to dietary intake. Am J Clin Nutr 1991, 53:628-637.
20. Swagell C.D., Henly D.C., Morris C.P. Regulation of human hepatocyte gene expression by fatty acids. Biochem Biophys Res Commun 2007, 362:374-380.
21. Kondoh Y., Kawada T., Urade R. Activation of caspase 3 in HepG2 cells by elaidic acid (t18:1). Biochim Biophys Acta 2007, 1771:500-505.
22. Vock C., Gleissner M., Klapper M., Doring F. Identification of palmitate-regulated genes in HepG2 cells by applying microarray analysis. Biochim Biophys Acta 2007, 1770:1283-1288.
23. Moberly J.B., Cole T.G., Alpers D.H., Schonfeld G. Oleic acid stimulation of apolipoprotein B secretion from HepG2 and Caco-2 cells occurs post-transcriptionally. Biochim Biophys Acta 1990, 1042:70-80.
24. Vock C., Gleissner M., Klapper M., Doring F. Oleate regulates genes controlled by signaling pathways of mitogen-activated protein kinase, insulin, and hypoxia. Nutr Res 2008, 28:681-689.
25. Dashti N., Feng Q., Franklin F.A. Long-term effects of cis and trans monounsaturated (18:1) and saturated (16:0) fatty acids on the synthesis and secretion of apolipoprotein A-I- and apolipoprotein B-containing lipoproteins in HepG2 cells. J Lipid Res 2000, 41:1980-1990.
26. Arrol S., Mackness M.I., Durrington P.N. The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2). Atherosclerosis 2000, 150:255-264.
27. Unlu M., Morgan M.E., Minden J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18:2071-2077.
28. Lilley K.S., Friedman D.B. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteomics 2004, 1:401-409.
29. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1:376-386.
30. Kitteringham N.R., Jenkins R.E., Lane C.S., Elliott V.L., Park B.K. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1229-1239.
31. Couloubaly S., Delomenie C., Rousseau D., Paul J.L., Grynberg A., Pourci M.L. Fatty acid incorporation in endothelial cells and effects on endothelial nitric oxide synthase. Eur J Clin Invest 2007, 37:692-699.
32. Ferreri C., Costantino C., Perrotta L., Landi L., Mulazzani Q.G., Chatgilialoglu C. Cis-trans isomerization of polyunsaturated fatty acid residues in phospholipids catalyzed by thiyl radicals. J Am Chem Soc 2001, 123:4459-4468.
33. Bury A. Analysis of protein and peptide mixtures Evaluation of three sodium dodecyl sulphate-polyacrylamide gel electrophoresis buffer systems. J Chromatogr A 1981, 213:491-500.
34. Kronvall G., Simmons A., Myhre E.B., Jonsson S. Specific absorption of human serum albumin, immunoglobulin A, and immunoglobulin G with selected strains of group A and G streptococci. Infect Immun 1979, 25:1-10.
35. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
36. Shevchenko A., Tomas H., Havlis J., Olsen J.V., Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 2006, 1:2856-2860.
37. Prakash A., Tomazela D.M., Frewen B., MacLean B., Merrihew G., Peterman S., et al. Expediting the development of targeted SRM assays: using data from shotgun proteomics to automate method development. J Proteome Res 2009, 8:2733-2739.
38. Florens L., Washburn M.P., Raine J.D., Anthony R.M., Grainger M., Haynes J.D., et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 2002, 419:520-526.
39. Gao J., Opiteck G.J., Friedrichs M.S., Dongre A.R., Hefta S.A. Changes in the protein expression of yeast as a function of carbon source. J Proteome Res 2003, 2:643-649.
40. Yamashita R., Fujiwara Y., Ikari K., Hamada K., Otomo A., Yasuda K., et al. Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry. Mol Cell Biochem 2007, 298:83-92.
41. Cao J., Hu Y., Shen C., Yao J., Wei L., Yang F., et al. Nanozeolite-driven approach for enrichment of secretory proteins in human hepatocellular carcinoma cells. Proteomics 2009, 9:4881-4888.
42. Metodieva G., Greenwood C., Alldridge L., Sauven P., Metodiev M. A peptide-centric approach to breast cancer biomarker discovery utilizing label-free multiple reaction monitoring mass spectrometry. Proteomics Clin Appl 2009, 3:78-82.
43. Shen Y., Berger S.J., Anderson G.A., Smith R.D. High-efficiency capillary isoelectric focusing of peptides. Anal Chem 2000, 72:2154-2159.
44. Bantscheff M., Schirle M., Sweetman G., Rick J., Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 2007, 389:1017-1031.
45. Ghazalpour A., Bennett B., Petyuk V.A., Orozco L., Hagopian R., Mungrue I.N., et al. Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet 2011, 7:e1001393.
46. Amacher D.E. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 1998, 27:119-130.
47. Alam S.Q., Ren Y.F., Alam B.S. Effect of dietary trans fatty acids on some membrane-associated enzymes and receptors in rat heart. Lipids 1989, 24:39-44.
48. Keshishian H., Addona T., Burgess M., Mani D.R., Shi X., Kuhn E., et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2009, 8:2339-2349.
49. Maier T., Guell M., Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett 2009, 583:3966-3973.
50. Schmidt R.J., Beyer T.P., Bensch W.R., Qian Y.W., Lin A., Kowala M., et al. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun 2008, 370:634-640.
51. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Manttari M., Heinonen O.P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85:37-45.
52. Ix J.H., Chertow G.M., Shlipak M.G., Brandenburg V.M., Ketteler M., Whooley M.A. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007, 115:2533-2539.
53. Liu P., Sun M., Sader S. Matrix metalloproteinases in cardiovascular disease. Can J Cardiol 2006, 22(Suppl. B):25B-30B.
54. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000, 342:1792-1801.
55. Rao L.V., Rapaport S.I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987, 69:645-651.
56. Novotny W.F., Girard T.J., Miletich J.P., Broze G.J. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989, 264:18832-18837.
57. Heald A.H., Cruickshank J.K., Riste L.K., Cade J.E., Anderson S., Greenhalgh A., et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001, 44:333-339.
58. Laughlin G.A., Barrett-Connor E., Criqui M.H., Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004, 89:114-120.
59. Reinehr T., Kleber M., Toschke A.M., Woelfle J., Roth C.L. Longitudinal association between IGFBP-1 levels and parameters of the metabolic syndrome in obese children before and after weight loss. Int J Pediatr Obes 2011, 6:236-243.
60. Benzinou M., Creemers J.W., Choquet H., Lobbens S., Dina C., Durand E., et al. Common nonsynonymous variants in PCSK1 confer risk of obesity. Nat Genet 2008, 40:943-945.
61. Jackson R.S., Creemers J.W., Ohagi S., Raffin-Sanson M.L., Sanders L., Montague C.T., et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997, 16:303-306.
62. Loftus T.M., Jaworsky D.E., Frehywot G.L., Townsend C.A., Ronnett G.V., Lane M.D., et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000, 288:2379-2381.
63. Moreno-Navarrete J.M., Botas P., Valdes S., Ortega F.J., Delgado E., Vazquez-Martin A., et al. Val1483Ile in FASN gene is linked to central obesity and insulin sensitivity in adult white men. Obesity (Silver Spring) 2009, 17:1755-1761.
64. Fernandez-Real J.M., Menendez J.A., Moreno-Navarrete J.M., Bluher M., Vazquez-Martin A., Vazquez M.J., et al. Extracellular fatty acid synthase: a possible surrogate biomarker of insulin resistance. Diabetes 2010, 59:1506-1511.
65. Micha R., Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nat Rev Endocrinol 2009, 5:335-344.